- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01132716
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
January 19, 2018 updated by: Roxane Laboratories
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fed Conditions
The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fed conditions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Dakota
-
Fargo, North Dakota, United States, 58104
- PRACS Institute, Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to valacyclovir hydrochloride or any comparable or similar product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
bioequivalence determined by statistical comparison Cmax
Time Frame: 8 days
|
8 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
September 1, 2006
Study Completion (Actual)
September 1, 2006
Study Registration Dates
First Submitted
May 25, 2010
First Submitted That Met QC Criteria
May 27, 2010
First Posted (Estimate)
May 28, 2010
Study Record Updates
Last Update Posted (Actual)
January 23, 2018
Last Update Submitted That Met QC Criteria
January 19, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Virus Diseases
- Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- DNA Virus Infections
- Skin Diseases, Infectious
- Skin Diseases, Viral
- Herpesviridae Infections
- Varicella Zoster Virus Infection
- Herpes Zoster
- Herpes Simplex
- Herpes Genitalis
- Anti-Infective Agents
- Antiviral Agents
- Valacyclovir
Other Study ID Numbers
- VALA-T1000-PVFD-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Herpes Zoster
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineCanada, Spain, Korea, Republic of, United Kingdom, France, Czechia
-
Merck Sharp & Dohme LLCCompletedHerpes Zoster | Herpes Zoster-related Complications
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Estonia, Canada
-
Ohio State UniversityCompletedHerpes Zoster DiseaseUnited States
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Canada, Belgium
-
GlaxoSmithKlineCompletedHerpes Zoster | Herpes Zoster VaccineUnited States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
-
Tanta UniversityNot yet recruitingAcute Herpes Zoster Pain Managment
-
Northwestern UniversityBausch & Lomb IncorporatedTerminatedHerpes Zoster KeratitisUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Centrexion TherapeuticsTerminatedAcute-onset Herpes Zoster PainAustralia
Clinical Trials on Valacyclovir Hydrochloride
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
University of MinnesotaCompletedEpstein-Barr Virus Infections | Cytomegalovirus Infections | Transplantation InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...Glaxo WellcomeWithdrawnHIV Infections | Herpes Simplex | Chickenpox
-
GlaxoSmithKlineTerminatedHerpes GenitalisUnited States, Australia, Hong Kong
-
Ranbaxy Laboratories LimitedCompleted
-
National Institute of Allergy and Infectious Diseases...Glaxo WellcomeCompletedHIV Infections | Cytomegalovirus InfectionsUnited States, Canada, Italy, United Kingdom, Australia, Denmark, France, Germany, Sweden, Switzerland
-
Roxane LaboratoriesCompletedHerpes Zoster | Genital Herpes | ShinglesUnited States
-
Ranbaxy Laboratories LimitedCompleted
-
Glaxo WellcomeUnknownHIV Infections | Herpes Simplex | Herpes GenitalisUnited States, Canada